Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study
Summary Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patient...
Gespeichert in:
| Veröffentlicht in: | Investigational new drugs 2020-12, Vol.38 (6), p.1915-1920 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1920 |
|---|---|
| container_issue | 6 |
| container_start_page | 1915 |
| container_title | Investigational new drugs |
| container_volume | 38 |
| creator | Nasu, Shingo Suzuki, Hidekazu Shiroyama, Takayuki Tanaka, Ayako Samejima, Yumiko Kanai, Tomohiro Noda, Yoshimi Morishita, Naoko Okamoto, Norio Hirashima, Tomonori |
| description | Summary
Background
Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD.
Methods
We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD.
Results
Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients.
Conclusions
According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD. |
| doi_str_mv | 10.1007/s10637-020-00963-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32542461</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2471166540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-ad031308c27cf7dc69746403c94b967f4c6b0aa7a747fe16db4362097b89745d3</originalsourceid><addsrcrecordid>eNqNkc-KFDEQxoMo7jj6Ah4k4EWQaNJJJ9PelsF_sOBBPTfpdGXN0p2MSdphXsZntWZnXMGDeEpIfl9VffUR8lTwV4Jz87oIrqVhvOGM805Ltr9HVqI1knGt9H2y4kIbprvOXJBHpdxwzmVn1ENyIZtWNUqLFfn52XqoB2rjSMH74Kw70OSp9baGGAbqU6b1G9CawdYZYj3-xhRZme00MQfTRKclXlNno4OM_DSlfcCHVMIM-bYKC3FcHIw0xAq51FCDPcvGUMAWeEMvaYaaU9mBq-EH0FKX8fCYPPB2KvDkfK7J13dvv2w_sKtP7z9uL6-YU0pUZkcuheQb1xjnzeg02tSKS9epodPGK6cHbq2xRhkPQo-DkrrhnRk2SLajXJMXp7q7nL4vUGo_h3L0ZiOkpfSNEgp33CiF6PO_0Ju05IjTIWWE0LrFzmvSnCiHlkoG3-9ymG0-9IL3x_T6U3o9ptffptfvUfTsXHoZZhjvJL_jQuDlCdjDkHxxAXDndxjmi62VaFu88SO9-X96GyomnuI2LbGiVJ6kBfF4DfmPyX_M_wuihciZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471166540</pqid></control><display><type>article</type><title>Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Nasu, Shingo ; Suzuki, Hidekazu ; Shiroyama, Takayuki ; Tanaka, Ayako ; Samejima, Yumiko ; Kanai, Tomohiro ; Noda, Yoshimi ; Morishita, Naoko ; Okamoto, Norio ; Hirashima, Tomonori</creator><creatorcontrib>Nasu, Shingo ; Suzuki, Hidekazu ; Shiroyama, Takayuki ; Tanaka, Ayako ; Samejima, Yumiko ; Kanai, Tomohiro ; Noda, Yoshimi ; Morishita, Naoko ; Okamoto, Norio ; Hirashima, Tomonori</creatorcontrib><description>Summary
Background
Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD.
Methods
We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD.
Results
Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients.
Conclusions
According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/s10637-020-00963-w</identifier><identifier>PMID: 32542461</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject><![CDATA[Acrylamides - adverse effects ; Adult ; Afatinib - administration & dosage ; Afatinib - adverse effects ; Aged ; Aged, 80 and over ; Aniline Compounds - adverse effects ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Disease control ; Epidermal growth factor ; Epidermal growth factor receptors ; Female ; Growth factors ; Health services ; Humans ; Life Sciences & Biomedicine ; Lung cancer ; Lung diseases ; Lung Diseases, Interstitial - chemically induced ; Lung Neoplasms - drug therapy ; Male ; Medicine ; Medicine & Public Health ; Mutation ; Non-small cell lung carcinoma ; Oncology ; Patients ; Pharmacology & Pharmacy ; Pharmacology/Toxicology ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Retrospective Studies ; Safety ; Science & Technology ; Short Report ; Small cell lung carcinoma ; Steroids ; Targeted cancer therapy]]></subject><ispartof>Investigational new drugs, 2020-12, Vol.38 (6), p.1915-1920</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000540415500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c441t-ad031308c27cf7dc69746403c94b967f4c6b0aa7a747fe16db4362097b89745d3</citedby><cites>FETCH-LOGICAL-c441t-ad031308c27cf7dc69746403c94b967f4c6b0aa7a747fe16db4362097b89745d3</cites><orcidid>0000-0003-1965-850X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10637-020-00963-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10637-020-00963-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32542461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nasu, Shingo</creatorcontrib><creatorcontrib>Suzuki, Hidekazu</creatorcontrib><creatorcontrib>Shiroyama, Takayuki</creatorcontrib><creatorcontrib>Tanaka, Ayako</creatorcontrib><creatorcontrib>Samejima, Yumiko</creatorcontrib><creatorcontrib>Kanai, Tomohiro</creatorcontrib><creatorcontrib>Noda, Yoshimi</creatorcontrib><creatorcontrib>Morishita, Naoko</creatorcontrib><creatorcontrib>Okamoto, Norio</creatorcontrib><creatorcontrib>Hirashima, Tomonori</creatorcontrib><title>Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><addtitle>INVEST NEW DRUG</addtitle><addtitle>Invest New Drugs</addtitle><description>Summary
Background
Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD.
Methods
We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD.
Results
Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients.
Conclusions
According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD.</description><subject>Acrylamides - adverse effects</subject><subject>Adult</subject><subject>Afatinib - administration & dosage</subject><subject>Afatinib - adverse effects</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aniline Compounds - adverse effects</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Disease control</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>Female</subject><subject>Growth factors</subject><subject>Health services</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial - chemically induced</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmacology & Pharmacy</subject><subject>Pharmacology/Toxicology</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Retrospective Studies</subject><subject>Safety</subject><subject>Science & Technology</subject><subject>Short Report</subject><subject>Small cell lung carcinoma</subject><subject>Steroids</subject><subject>Targeted cancer therapy</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkc-KFDEQxoMo7jj6Ah4k4EWQaNJJJ9PelsF_sOBBPTfpdGXN0p2MSdphXsZntWZnXMGDeEpIfl9VffUR8lTwV4Jz87oIrqVhvOGM805Ltr9HVqI1knGt9H2y4kIbprvOXJBHpdxwzmVn1ENyIZtWNUqLFfn52XqoB2rjSMH74Kw70OSp9baGGAbqU6b1G9CawdYZYj3-xhRZme00MQfTRKclXlNno4OM_DSlfcCHVMIM-bYKC3FcHIw0xAq51FCDPcvGUMAWeEMvaYaaU9mBq-EH0FKX8fCYPPB2KvDkfK7J13dvv2w_sKtP7z9uL6-YU0pUZkcuheQb1xjnzeg02tSKS9epodPGK6cHbq2xRhkPQo-DkrrhnRk2SLajXJMXp7q7nL4vUGo_h3L0ZiOkpfSNEgp33CiF6PO_0Ju05IjTIWWE0LrFzmvSnCiHlkoG3-9ymG0-9IL3x_T6U3o9ptffptfvUfTsXHoZZhjvJL_jQuDlCdjDkHxxAXDndxjmi62VaFu88SO9-X96GyomnuI2LbGiVJ6kBfF4DfmPyX_M_wuihciZ</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Nasu, Shingo</creator><creator>Suzuki, Hidekazu</creator><creator>Shiroyama, Takayuki</creator><creator>Tanaka, Ayako</creator><creator>Samejima, Yumiko</creator><creator>Kanai, Tomohiro</creator><creator>Noda, Yoshimi</creator><creator>Morishita, Naoko</creator><creator>Okamoto, Norio</creator><creator>Hirashima, Tomonori</creator><general>Springer US</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1965-850X</orcidid></search><sort><creationdate>20201201</creationdate><title>Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study</title><author>Nasu, Shingo ; Suzuki, Hidekazu ; Shiroyama, Takayuki ; Tanaka, Ayako ; Samejima, Yumiko ; Kanai, Tomohiro ; Noda, Yoshimi ; Morishita, Naoko ; Okamoto, Norio ; Hirashima, Tomonori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-ad031308c27cf7dc69746403c94b967f4c6b0aa7a747fe16db4362097b89745d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acrylamides - adverse effects</topic><topic>Adult</topic><topic>Afatinib - administration & dosage</topic><topic>Afatinib - adverse effects</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aniline Compounds - adverse effects</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Disease control</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>Female</topic><topic>Growth factors</topic><topic>Health services</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial - chemically induced</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmacology & Pharmacy</topic><topic>Pharmacology/Toxicology</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Retrospective Studies</topic><topic>Safety</topic><topic>Science & Technology</topic><topic>Short Report</topic><topic>Small cell lung carcinoma</topic><topic>Steroids</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nasu, Shingo</creatorcontrib><creatorcontrib>Suzuki, Hidekazu</creatorcontrib><creatorcontrib>Shiroyama, Takayuki</creatorcontrib><creatorcontrib>Tanaka, Ayako</creatorcontrib><creatorcontrib>Samejima, Yumiko</creatorcontrib><creatorcontrib>Kanai, Tomohiro</creatorcontrib><creatorcontrib>Noda, Yoshimi</creatorcontrib><creatorcontrib>Morishita, Naoko</creatorcontrib><creatorcontrib>Okamoto, Norio</creatorcontrib><creatorcontrib>Hirashima, Tomonori</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nasu, Shingo</au><au>Suzuki, Hidekazu</au><au>Shiroyama, Takayuki</au><au>Tanaka, Ayako</au><au>Samejima, Yumiko</au><au>Kanai, Tomohiro</au><au>Noda, Yoshimi</au><au>Morishita, Naoko</au><au>Okamoto, Norio</au><au>Hirashima, Tomonori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study</atitle><jtitle>Investigational new drugs</jtitle><stitle>Invest New Drugs</stitle><stitle>INVEST NEW DRUG</stitle><addtitle>Invest New Drugs</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>38</volume><issue>6</issue><spage>1915</spage><epage>1920</epage><pages>1915-1920</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><abstract>Summary
Background
Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD.
Methods
We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD.
Results
Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients.
Conclusions
According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32542461</pmid><doi>10.1007/s10637-020-00963-w</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1965-850X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 2020-12, Vol.38 (6), p.1915-1920 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_pubmed_primary_32542461 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Acrylamides - adverse effects Adult Afatinib - administration & dosage Afatinib - adverse effects Aged Aged, 80 and over Aniline Compounds - adverse effects Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Disease control Epidermal growth factor Epidermal growth factor receptors Female Growth factors Health services Humans Life Sciences & Biomedicine Lung cancer Lung diseases Lung Diseases, Interstitial - chemically induced Lung Neoplasms - drug therapy Male Medicine Medicine & Public Health Mutation Non-small cell lung carcinoma Oncology Patients Pharmacology & Pharmacy Pharmacology/Toxicology Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Retrospective Studies Safety Science & Technology Short Report Small cell lung carcinoma Steroids Targeted cancer therapy |
| title | Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T22%3A59%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20afatinib%20for%20the%20treatment%20of%20non-small-cell%20lung%20cancer%20following%20osimertinib-induced%20interstitial%20lung%20disease:%20A%20retrospective%20study&rft.jtitle=Investigational%20new%20drugs&rft.au=Nasu,%20Shingo&rft.date=2020-12-01&rft.volume=38&rft.issue=6&rft.spage=1915&rft.epage=1920&rft.pages=1915-1920&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/s10637-020-00963-w&rft_dat=%3Cproquest_pubme%3E2471166540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471166540&rft_id=info:pmid/32542461&rfr_iscdi=true |